Relief Therapeutics' Lead Candidate Gets US Orphan Drug Tag In Sarcoidosis

by Vandana Singh, Benzinga Editor

August 3, 2021 6:34 AM | 29 seconds read |

The FDA has granted Orphan Drug Designation to Relief Therapeutics Holding AG's RLFTF for RLF-100 (aviptadil), an inhaled formulation, for sarcoidosis.
RLF-100 is a synthetic form of vasoactive intestinal peptide.
Sarcoidosis is a rare disease in which the inflammatory process involves the alveoli (air sacs), small bronchi, and small blood vessels.
RLF-100 is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19.
Price Action: RLFTF shares closed at $0.24 on Monday.
Related content: Benzinga's Full FDA Calendar.